Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 06 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Methylene Blue Injection, which will be available in two formulations. This approval allows Zydus to manufacture and market a generic version of the drug, providing a more affordable vial presentation compared to the traditional ampoule. The injection is indicated for treating methemoglobinemia in both pediatric and adult patients, and the US market for this product had significant annual sales.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases